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Abstract 
 
Protease-activated receptor 1 (PAR1), a G protein-coupled receptor (GPCR) for 
thrombin, has been correlated with cell proliferation. PAR1 is activated by the irreversibly 
proteolytic cleavage, internalized via clathrin-coated pits, and then sorted to lysosomes for 
degradation. Caveolae play important roles in both signaling transduction and internalization 
of several GPCRs. However, the role of caveolae in cellular signaling and trafficking of 
PAR1 is still unclear. In this study, we show that PAR1 was partially localized in caveolae. 
Disruption of caveolae by cholesterol depletion did not inhibit PAR1 internalization, 
indicating that internalization of PAR1 was not via caveolae. Of interest, activation of PAR1 
resulted in the phosphorylation of caveolin-1, a principal component of caveolae, on tyrosine 
14 by a Gi-linked Src kinase pathway and p38 mitogen-activated protein kinase. Analysis of 
immunoprecipitates from cells stimulated by PAR1 showed that phosphocaveolin-1 but not 
caveolin-1 with mutation at tyrosine 14 could bind to Csk. In addition, phosphocaveolin-1 
could not bind to CskS109C mutant with the defective SH2 domain. These results indicated 
that phosphocaveolin-1 was associated with the SH2 domain of Csk in response to PAR1 
activation. The association further resulted in a rapid decrease in Src kinase activity. Thus, 
PAR1-induced Src activation is negatively regulated by recruiting Csk through 
phosphocaveolin-1. Our results also reveal that phosphocaveolin-1 represents a novel effector 
of PAR1 to downregulate Src kinase activity. The downregulation of PAR1-induced Src 
activation mediated by phosphocaveolin-1 provides an additional mechanism for the 
termination of PAR1 signaling at its downstream molecules. 
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1. Introduction 
 
Protease-activated receptor 1 (PAR1), a G protein-coupled receptor (GPCR), mediates 
many actions of thrombin, including haemostasis, thrombosis, and cell proliferation. 
Thrombin-mediated cleavage at a specific site of the N-terminal domain of PAR1 unmasks an 
internal ligand to activate the receptor [1-3]. Due to the irreversibly proteolytic activation, 
activated PAR1 is rapidly internalized via clathrin-coated pits and sorted to lysosomes to 
terminate its signaling [4,5]. A synthetic peptide, SFLLRN, can mimic the action of thrombin 
and fully activate PAR1 [6]. After activation, PAR1 couples to several heterotrimeric G 
proteins and initiates downstream signaling pathways to mediate the actions of thrombin on 
cells [7]. In breast carcinoma cells, the level of PAR1 expression has been correlated with the 
degree of invasiveness [8]. In colon cancer cell lines, Src kinase has been shown to play a 
permissive role for PAR1-mediated cell proliferation [9]. At the molecular level, 
PAR1-induced Src kinase activation lies between Gi protein and the downstream 
Ras/mitogen-activated protein kinase cascade, which in turn results in PAR1 gene 
transcription and subsequent cell proliferation [10,11]. Therefore, the regulation of 
PAR1-induced Src activation might play important roles in proliferation and invasion of 
tumor cells. 
 
Caveolin-1 was first identified in v-Src transformed chicken embryo fibroblasts as a 
major tyrosine-phosphorylated protein [12]. This 21–24 kDa integral protein is the chief 
component of caveolae [13]. Caveolae appear as flask-shaped invaginations of 50–100 nm in 
the plasma membrane and constitute a subset of lipid rafts in cells with high concentrations of 
cholesterol [14,15]. Caveolar function is critically dependent on the level of cholesterol in the 
plasma membrane. Increasing evidence indicates that certain GPCRs, such as somatostatin 
receptor 2, endothelin receptor type A, and A1 adenosine receptor are endocytosed via 
caveolae [16-19]. In addition to serving as vesicular transporters, the function of caveolae has 
also been implicated in organizing and regulating the cellular signaling events of GPCRs. 
Angiotensin II type 1 receptor has been reported to move to caveolae to transactivate 
epidermal growth factor receptor (EGFR) [20,21]. Oxytocin receptors localized inside or 
outside caveolin-enriched microdomains couple to different G proteins and lead to different 
temporal patterns of mitogen-activated protein (MAP) kinase activation and EGFR 
transactivation [22]. Direct interaction of caveolin-1 with the heterotrimeric G proteins and 
its downstream molecules such as Src kinase has been shown to be able to negatively regulate 
their functions [23]. Thus, caveolin-1 may be critical in regulating the signaling cascade of 
GPCRs in caveolae. 
 
Caveolin-1 has been reported to be phosphorylated by Src kinase on tyrosine 14 [24]. 
Insulin, epidermal growth factor (EGF), platelet-derived growth factor (PDGF), vascular 
endothelial growth factor (VEGF), angiotensin II, and cellular stress can also induce this 
phosphorylation [25,30]. Phosphocaveolin-1 is localized in close to proximity to focal 
adhesions [31]. However, the functional significance of phosphocaveolin-1 is not clear. 
Under oxidative stress, phosphocaveolin-1 serves as a docking protein for recruiting 
C-terminal Src kinase (Csk) to Src kinase [29,32]. Csk, a tyrosine kinase, phosphorylates the 
negative regulatory site of tyrosine 527 of the Src family kinase and keeps it in an inactive 
conformation [33,34]. Such recruitment of Csk by phosphocaveolin-1 is important in the 
feedback regulation of Src kinase activity. In addition to oxidative stress, whether other 
stimuli mediate the regulation of Src kinase activity by the association of phosphocaveolin-1 
with Csk remains to be determined. 
Several GPCRs are localized in caveolae, in which their downstream signaling can be 
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regulated. Also, some GPCRs are internalized via caveolae. However, it is not known 
whether caveolae are also involved in the cellular signaling and internalization of PAR1. In 
the present study, we first examined whether PAR1 was localized in caveolae and 
internalized via caveolae. We then investigated whether activation of PAR1 can stimulate the 
phosphorylation of caveolin-1 on tyrosine 14 and determine its signal transduction pathways. 
Finally, we addressed the functional significance of phosphocaveolin-1 in response to PAR1 
activation by examining the ability of phosphocaveolin-1 to recruit Csk through the SH2 
domain of Csk and then to provide the feedback regulation of Src kinase activity. We herein 
report the molecular mechanism by which PAR1 regulates Src kinase activity through the 
phosphorylation of caveolin-1. 
 
 
2. Materials and methods 
 
2.1. Materials 
 
Synthetic peptide SFLLRN was synthesized by SynPep Crop. (Dublin, CA). Bovine 
albumin (BSA), 4-morpholineethanesulfonic acid (Mes), sucrose, nystatin, 
methyl-beta-cyclodextrin, pertussis toxin (PTX), and isopropyl β-d-thiogalactopyranoside 
(IPTG) were from Sigma (St. Louis, MO). PP1 and SB203580 were from Calbiochem 
(Darmstadt, Germany). One-step ABTS (2,2-azino-bis-3-ethylbenzthiazoline-6-sulfonic acid) 
was purchased from Pierce Biotechnology Inc. (Carlsbad, CA). Alexa 488-conjugated 
albumin was from Invitrogen Corp. (Carlsbad, CA). Anti-PAR1 1809 rabbit antiserum was 
generously provided by Dr. Shaun R. Coughlin at University of California, San Francisco, 
CA [35]. Polyclonal anti-caveolin antibody and monoclonal anti-phosphocaveolin-1 (clone 
56), anti-clathrin (clone 23), and anti-Csk (clone 52) antibodies were from BD Bioscience 
(San Jose, CA). Polyclonal anti-caveolin-1 antibody (sc-894) was from Santa Cruz 
Biotechnology Inc. (Santa Cruz, CA). Polyclonal anti-phospho-p38, anti-phospho-Src 
tyrosine 527 and anti-nonphospho-Src tyrosine 527 antibodies were from Cell Signaling 
Technology, Inc. (Beverly, MA). Monoclonal anti-FLAG M1 antibody was from Sigma. 
Tubulin-α Ab-1 (clone DM1A) antibody was from NeoMarker (Fremont, CA). Horseradish 
peroxidase-conjugated affinipure goat anti-mouse or anti-rabbit antibodies, fluorescein 
(FITC)-conjugated affinipure goat anti-mouse IgG and rhodamine (TRITC)-conjugated 
affinipure goat anti-rabbit IgG were from Jackson ImmunoResearch Laboratories Inc. (West 
Grove, PA). 
 
 
2.2. cDNAs and cell lines 
 
The cDNA encoding FLAG-tagged PAR1 in the pBJ vector was a generous gift of Dr. 
Shaun R. Coughlin [36]. A kinase inactive mutant of p38 MAP kinase (p38AF) was 
generously provided by Dr. Amira Klip at University of Toronto, Canada [37]. The cDNAs 
encoding Csk and CskS109C mutant in pEF-HA vectors were the generous gifts of Dr. 
Walter Eckhart at Salk Institute, La Jolla, CA [38]. A cDNA encoding wild-type human 
caveolin-1 in the pCEP4 vector was a gift from Dr. Harold A. Chapman at University of 
California, San Francisco, CA. The cDNAs encoding human caveolin-1 was subjected to 
site-directed mutagenesis by polymerase chain reaction (PCR) to convert codon 14 from Tyr 
(TAC) to Phe (TTC) and the PCR fragments were then subcloned into the pCEP4 vector, 
resulting in the human caveolin-1/Y14F mutant. Mutagenesis was done by Te-Jung Lu at 
National Cheng Kung University, and the mutation was confirmed by DNA sequencing 
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analysis. Human embryonic kidney 293 (HEK 293) cells stably expressing FLAG-tagged 
PAR1 and COS7 cells were cultured in minimum essential medium with Earle's salts and 
Dulbecoo's modified Eagle's medium (Invitrogen), respectively, and supplemented with 10% 
fetal bovine serum (Hyclone Laboratories, Logan, UT) in a humidified atmosphere 
containing 5% CO2. 
 
 
2.3. Transfection methods 
 
For transient transfection, COS7 or HEK 293 cells were transfected with 0.8 μg of 
DNA and 1.6 μl of Lipofectamine 2000 (Invitrogen) in 24-well dishes according to the 
manufacturer's instructions (Invitrogen). To transfect cells in different formats, the amounts 
of Lipofectamine 2000 and DNA were scaled up in proportion to the relative surface area of 
the cultured dishes. 
 
 
2.4. Detergent-free purification of caveolin-enriched membrane fraction 
 
COS7 cells with 95% of confluence in 150-mm dishes transiently transfected with 
60 μg plasmids of FLAG-tagged PAR1 were used to prepare caveolin-enriched membrane 
fractions by a detergent-free sodium carbonate method, essentially as described 
previously [39]. Briefly, cells were scraped into 2 ml of 500 mM sodium carbonate buffer, 
pH 11.0, containing 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, and 1 mM 
Na3VO4. The cell suspension was sonicated thirty times with 60% amplitude and 0.5 cycle on 
ice using an UP 50H ultrasonicator (Dr. Hielscher GmbH, Teltow, Germany), and the 
insoluble material was removed by centrifugation. The supernatant was adjusted to 45% 
sucrose by the addition of 2 ml of 90% sucrose prepared in Mes-buffered saline (MBS) 
containing 25 mM Mes, pH 6.5, and 0.15 M NaCl, overlaid with 4 ml of 35% sucrose and 
4 ml of 5% sucrose both in MBS containing 250 mM sodium carbonate, and centrifuged at 
4 °C for 18 h at 39,000 rpm in a Beckman SW41 rotor. After centrifugation, twelve 1-ml 
fractions were collected, and aliquots of each fraction were subjected to SDS-PAGE and 
western blot analysis with either anti-FLAG M1 or anti-caveolin antibodies. 
 
 
2.5. Internalization assays 
 
HEK 293 cells stably expressing FLAG-tagged PAR1 were plated in 24-well cell 
culture plates (BD Primaria™) at the density of 3 × 105 cells per well and grown overnight. 
Cells were then incubated in serum-free medium containing 20 mM HEPES, pH 7.4, and 
1 mg/ml BSA at 37 °C for 1 h. After serum starvation, cells were pretreated with 400 mM 
sucrose, 7.5 mM methyl-beta-cyclodextrin, or 50 μg/ml nystatin for 90 min and then were 
treated in the absence or presence of 100 μM SFLLRN at 37 °C for the indicated times. Cells 
were fixed with 4% paraformaldehyde (PFA) at 4 °C for 10 min and washed once with 
phosphate-buffered saline (PBS). Then, cells were incubated with anti-FLAG M1 antibody 
for 1 h, washed and then incubated with horseradish peroxidase-conjugated goat anti-mouse 
IgG secondary antibody for 1 h. Finally, cells were washed and incubated with one-step 
ABTS (the substrate of horseradish peroxidase) for 30 min. The aliquots were transferred to a 
96-well dish and the optical density was then determined at 405 nm using a model 550 
microplate reader (BioRad Laboratories, Inc., Hercules, CA). 
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2.6. Confocal microscopy 
 
COS7 cells transiently transfected with FLAG-tagged PAR1 were split onto coverslips 
in a 6-well dish. Cells were pre-incubated in serum-free medium containing 20 mM HEPES, 
pH 7.4, and 1 mg/ml BSA at 37 °C for 1 h and incubated in the absence or presence of 
100 μM SFLLRN for 30 min or 50 μg/ml Alexa 488-conjugated albumin for 5 or 30 min. 
Cells were washed three times with PBS, fixed with 4% PFA at 4 °C for 10 min, washed 
twice with the quench buffer (PBS, pH 7.4, containing 1 mg/ml BSA and 150 mM sodium 
acetate), and permeabilized with the quench buffer containing 0.1% saponine at room 
temperature for 20 min. Cells were incubated with anti-FLAG M1 antibody or 1809 rabbit 
antiserum to label PAR1, anti-caveolin antibody to label caveolin, or anti-clathrin antibody to 
label clathrin for 1 h. Cells were then washed and incubated with species-specific 
fluorophore-conjugated secondary antibodies for 1 h at room temperature. Cells were washed 
four times with PBS and mounted with the SlowFade anti-fade reagent (Invitrogen). Confocal 
images were collected using a Zeiss Axioplan2 LSM510 confocal microscope fitted with a 
Plan-Neofluar 40X/NA 0.75 objective or a Plan-Neofluar 63X/NA 1.2 water immersion 
objective. The final composite image was created using Adobe Photoshop 7.0. 
 
 
2.7. Immunoprecipitation 
 
FLAG-tagged PAR1 was immunoprecipitated by using the FLAG immunoprecipitation 
kit (Sigma). Briefly, confluent COS7 cells in 100-mm dishes transiently cotransfected with 
12 μg plasmids of human caveolin-1 together with 12 μg plasmids of FLAG-tagged PAR1 or 
pBJ vector were serum starved for 24 h. Cells were lysed in ice-cold lysis buffer containing 
50 mM Tris–HCl, pH 7.4, with 150 mM NaCl, 1 mM EDTA, 1% triton X-100, 1 mM 
phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, and 1 mM Na3VO4. The insoluble 
material was removed by centrifugation at 13,000 ×g for 15 min prior to the incubation with 
anti-FLAG M2 affinity gel at 4 °C for 2 h. The FLAG-tagged proteins were eluted by the 
incubation in 100 μl of Tris-buffered saline (TBS) containing 150 ng/μl 3X FLAG peptide 
(Sigma) at 4 °C for 1 h. The eluted proteins were recovered by centrifugation at 12000 ×g for 
2 min, and the supernatant was subjected to SDS-PAGE and western blot analysis. 
 
HA-tagged Csk was immunoprecipitated by using the anti-HA immunoprecipitation kit 
(Sigma). Briefly, confluent HEK 293 cells in 100-mm dishes transiently transfected with 
12 μg plasmids of HA-tagged Csk or HA-tagged CskS109C together with 12 μg plasmids of 
human caveolin-1, human caveolin-1/Y14F or pCEP4 vector were incubated in the absence 
or presence of 100 μM SFLLRN at 37 °C for 10 min, washed with PBS, and lysed in ice-cold 
CelLytic M buffer (Sigma) containing 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml 
aprotinin, and 1 mM Na3VO4. The insoluble material was removed by centrifugation, and the 
supernatant was incubated with 10 μl of anti-HA-agarose for 2 h with gentle mixing at 4 °C. 
HA-tagged Csk and its associated proteins were eluted by incubating with 100 μl of sample 
buffer containing 62.5 mM Tris–HCl, pH 6.8, 2% SDS, and 10% glycerol at 95 °C for 5 min. 
The eluted proteins were recovered by centrifugation at 12000 ×g for 2 min, and the 
supernatant was subjected to SDS-PAGE and western blot analysis. 
 
 
2.8. Western blot analysis 
 
To detect phosphocaveolin-1, cells were lysed in 500 mM sodium carbonate buffer, pH 
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11.0, containing 1 mM phenylmethylsulfonyl fluoride, 10 μg/ml aprotinin, and 1 mM 
Na3VO4[40]. The cell suspension was sonicated thirty times with 60% amplitude and 0.5 
cycle on ice using an UP 50H ultrasonicator. To detect other proteins of interest, cells were 
lysed with lysis buffer containing 50 mM NaH2PO4, pH 7.2, 150 mM NaCl, 6 mM sodium 
deoxycholate and 1% NP-40. The insoluble material was removed by centrifugation at 12000 
×g for 15 min. Protein concentration was determined by the BCA assay kit (Pierce). Samples 
containing equal amounts of proteins were resolved by SDS-PAGE and transferred to 
polyvinylidene difluoride membrane. Western blotting was performed using primary 
antibodies against the proteins of interest, and horseradish peroxidase-conjugated secondary 
antibodies (1:3000 dilution) were used to visualize bound primary antibodies by an enhanced 
chemiluminescence assay (ECL) (Amersham, Piscataway, NJ). 
 
 
 
3. Results 
 
3.1. Association of PAR1 and caveolin-1 
 
To investigate whether PAR1 is localized in caveolae, three approaches were used. In 
the first approach, caveolin-enriched fractions were separated from the bulk of cellular 
membranes and cytosolic proteins by using an established method based on the 
buoyant-density properties of caveolae [39]. COS7 cells transiently transfected with 
FLAG-tagged PAR1 were lysed in a detergent-free sodium carbonate buffer, and the lysates 
were fractionated on a discontinuous sucrose gradient. Equal volumes of each of the twelve 
collected fractions were subjected to western blot analysis for PAR1 and endogenous 
caveolin, an integral component of caveolar membrane. Because of the property of light 
buoyancy, caveolar membrane was floated between 5–35% of sucrose gradient. As shown 
in Fig. 1A, caveolin was predominantly recovered in the fractions 4 and 5 (5–35% of sucrose 
gradient). Before SFLLRN stimulation, a portion of PAR1 also appeared in the 
caveolin-enriched fractions 4 and 5, and the rest of PAR1 was recovered in the fractions 7 to 
12. However, after SFLLRN stimulation for 30 min, the distribution of PAR1 was similar to 
that before the stimulation (Fig. 1A). The results suggest that PAR1 is partially localized in 
caveolae both before and after agonist stimulation. Second, we attempted to determine 
whether PAR1 and caveolin-1 were physically associated with each other in COS7 cells by 
immunoprecipitation. In cells cotransfected with the plasmids of human caveolin-1 and 
FLAG-tagged PAR1, significant amounts of caveolin-1 and PAR1 were detected when 
FLAG-tagged PAR1 was immunoprecipitated with anti-FLAG M2 affinity gel. However, 
almost no caveolin-1 could be detected in the control cells cotransfected with human 
caveolin-1 and pBJ vector (Fig. 1B). Therefore, PAR1 might directly interact with caveolin-1 
in COS7 cells. In the final approach, the distribution of PAR1 and the endogenous caveolin 
was examined by confocal microscopy in COS7 cells transiently transfected with 
FLAG-tagged PAR1. We found that PAR1 was partially colocalized with caveolin along the 
cell periphery without agonist stimulation (Fig. 2A, a–c). Taken together, these results 
indicate that a portion of PAR1 is localized in caveolae at the cell membrane and directly 
interacts with caveolin-1 even in the absence of PAR1 agonist. 
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Fig. 1. Association of PAR1 and caveolin-1 in COS7 cells. A) Co-fractionation of PAR1 and caveolin. 
COS7 cells transiently transfected with FLAG-tagged PAR1 were serum starved, incubated in the 
absence or presence of 100 μM SFLLRN at 37 °C for 30 min, homogenized, and fractionated on a 
discontinuous sucrose gradient. Sucrose-gradient fractions were collected from top to bottom, and 
equal volumes of each fraction were immunoblotted with anti-FLAG M1 or anti-caveolin antibodies. 
B) Coimmunoprecipitation of FLAG-tagged PAR1 and caveolin-1. COS7 cells were cotransfected 
with the plasmids of human caveolin-1 and FLAG-tagged PAR1 or the plasmids of human caveolin-1 
and pBJ vector. After 48-h transfection, PAR1 was immunoprecipitated (IP) with anti-FLAG M2 
affinity gel. Whole cell lysates and immunoprecipitates (IP) were immunoblotted with anti-FLAG M1 
or anti-caveolin antibody. Similar results were obtained in two independent experiments. 
 
 
3.2. Caveolae-independent and clathrin-dependent internalization of PAR1 
 
Partial localization of PAR1 in caveolae raises the possibility that PAR1 might be 
internalized via caveolae after agonist stimulation. Confocal microscopy was employed to 
examine whether PAR1 is colocalized with caveolin-1 in COS7 cells after agonist stimulation. 
In cells transfected with FLAG-tagged PAR1, exposure to SFLLRN for 30 min caused 
internalization of PAR1 into endocytic vesicles (green), whereas little or no internalized 
receptor was colocalized with caveolin (red) (Fig. 2A, d–f). In contrast, the internalized 
PAR1 (green) was colocalized with clathrin (red) in the presence of agonist stimulation (Fig. 
2B, d–f). Since the uptake of albumin has been reported to be via caveolae [41], we then 
further determined whether the machinery of caveolin-mediated internalization is normal by 
monitoring the albumin uptake in COS7 cells transiently transfected with FLAG-tagged 
PAR1. As the time of incubation with albumin increased from 5 to 30 min, additional Alexa 
488-conjugated albumin (green) was colocalized with caveolin (red) (Fig. 2C). Thus, the 
machinery of caveolin-mediated internalization in these cells is normal. These results indicate 
that PAR1 might not be internalized via caveolae but through a clathrin-dependent 
mechanism in COS7 cells. 
 
To further investigate whether caveolae are involved in PAR1 internalization, nystatin 
and methyl-beta-cyclodextrin, sterol-binding agents, were used to block caveolae formation 
in HEK 293 cells stably expressing PAR1 [14],15]. The levels of PAR1 on the cell surface 
were determined by modified ELISA. When cells were stimulated with SFLLRN for 5 min, 
approximately 75% of PAR1 was rapidly internalized into the cells, and the amount of 
internalized PAR1 almost reached a maximum. In cells pretreated with nystatin or 
methyl-beta-cyclodextrin, PAR1 was also rapidly internalized into the cells after SFLLRN 
stimulation, and the rate of PAR1 internalization was similar to that in the control cells. On 
the contrary, only about 20% of PAR1 was internalized into the cells pretreated with sucrose, 
which is known to specifically inhibit clathrin-dependent endocytosis [42,43]. The rate of 
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internalization of PAR1 in cells pretreated with sucrose was much slower than that in the 
control cells (Fig. 2D). This result indicates that internalization of PAR1 is not inhibited by 
the disruption of caveolae but is clathrin-dependent in HEK 293 cells. Thus, internalization of 
PAR1 is not via caveolae in both COS7 and HEK 293 cells. 
 
 
 
 
Fig. 2. Caveolae-independent and clathrin-dependent internalization of PAR1. A) Colocalization of 
PAR1 and caveolin. COS7 cells transiently transfected with FLAG-tagged PAR1 were grown on 
coverslips and incubated in the absence or presence of 100 μM SFLLRN at 37 °C for 30 min. Cells 
were then immunostained for PAR1 (green) or caveolin (red). B) Colocalization of PAR1 and clathrin. 
Cells were treated as in A and immunostained for PAR1 (green) or clathrin (red). C) Colocalization of 
albumin and caveolin. COS7 cells transiently transfected with FLAG-tagged PAR1 were incubated in 
the absence or presence of 50 μg/ml Alexa 488-conjugated albumin at 37 °C for 5 or 30 min. Cells 
were then immunostained for caveolin (red). Protein colocalization is represented as yellow on the 
merged image. Scale bar, 10 μm. D, Effect of pharmacological inhibitors on the internalization of 
PAR1. HEK 293 cells stably expressing PAR1 were pre-incubated in the absence (●) or presence of 
50 μg/ml nystatin (Δ), 7.5 mM methyl-beta-cyclodextrin (□), or 400 mM sucrose (○) for 90 min. They 
were then stimulated with 100 μM SFLLRN at 37 °C for 5, 15, or 60 min. Levels of the receptor on the 
cell surface were determined by performing modified ELISA. The amount of PAR1 on the cell surface 
at the time zero was designated as the 100% point. Results shown are triplicate determinations from a 
single experiment that was repeated twice with essentially similar results. 
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3.3. Characterization of PAR1-induced phosphorylation of caveolin-1 on tyrosine 14 in 
COS7 cells and HEK 293 cells 
 
Since PAR1 is partially localized in caveolae, we then determined whether activated 
PAR1 could induce phosphorylation of caveolin-1 on tyrosine 14. The time course and dose 
response of PAR1-induced phosphorylation of caveolin-1 were studied in COS7 cells 
transiently transfected with FLAG-tagged PAR1 and HEK 293 cells stably expressing 
FLAG-tagged PAR1. After stimulation with 100 μM SFLLRN, phosphorylation of 
caveolin-1 on tyrosine 14 was transiently induced in both COS7 and HEK 293 cells (Fig. 3A). 
Such induction started at about 5 min and reached a maximum at around 15 min (Fig. 3A). 
The phosphorylation of caveolin-1 decreased gradually after 20 min (Fig. 3A). When both 
cells were stimulated with increased concentration of SFLLRN from 10 to 500 μM for 
15 min, caveolin-1 was phosphorylated in a concentration-dependent manner with 
pronounced effect at the SFLLRN concentration of 100 and 500 μM (Fig. 3B). The 
phosphorylation of caveolin-1 induced by PAR1 was not due to the protein expression of 
caveolin-1, since the expression of caveolin-1 did not change under the SFLLRN stimulation. 
The equivalent levels of tubulin also verified the uniform loading (Fig. 3A and B, the bottom 
panels). These results indicate that activated PAR1 could induce phosphorylation of 
caveolin-1 on tyrosine 14. 
 
 
3.4. Involvement of p38 MAP kinase in PAR1-induced phosphorylation of caveolin-1 
 
It has been known that the phosphorylation of caveolin-1 can be mediated by p38 MAP 
kinase [30]. In addition, p38 MAP kinase is activated by PAR1 in platelets and several 
established cell lines [44-46]. To determine whether p38 MAP kinase is involved in 
PAR1-induced phosphorylation of caveolin-1 on tyrosine 14, a selective p38 MAP kinase 
inhibitor, SB203580, was used. The p38 MAP kinase activity was inhibited in HEK 293 cells 
pretreated with SB203580 for 2 h prior to SFLLRN stimulation for 15 min (Fig. 4A, the 
bottom panel). Moreover, this pretreatment also resulted in partial inhibition of the 
phosphorylation of caveolin-1 stimulated by SFLLRN (Fig. 4A and B). 
 
To further verify the involvement of p38 MAP kinase in PAR1-induced 
phosphorylation of caveolin-1 on tyrosine 14, a dominant-negative form of p38 MAP kinase 
with the replacement of two activating phosphorylation sites by alanine and phenylalanine 
(p38AF) was used. In these experiments, HEK 293 cells were transiently transfected with a 
plasmid containing a gene encoding the dominant negative p38 MAP kinase under the control 
of the lac operon. Treatment of the cells with IPTG overrides the transcriptional repression, 
thereby allowing expression of this dominant-negative p38 MAP kinase. The cells were left 
untreated or treated for 48 h with IPTG and then stimulated with SFLLRN for 15 min. In 
cells without IPTG treatment, the levels of phosphorylation of both p38 MAP kinase and 
caveolin-1 increased under SFLLRN stimulation (Fig. 4C and D). Expression of the dominant 
negative p38 MAP kinase by IPTG treatment attenuated the phosphorylation of both p38 
MAP kinase and caveolin-1 (Fig. 4C and D). These results indicate that p38 MAP kinase 
could mediate PAR1-induced phosphorylation of caveolin-1 on tyrosine 14. 
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Fig. 3. Characterization of PAR1-induced phosphorylation of caveolin-1 on tyrosine 14 in COS7 and 
HEK 293 cells. A) Time course of PAR1-induced phosphorylation of caveolin-1 on tyrosine 14. 
COS7 cells transiently transfected with FLAG-tagged PAR1 and HEK 293 cells stably expressing 
FLAG-tagged PAR1 were serum starved for 24 h. Both cells were incubated with 100 μM SFLLRN 
at 37 °C from 2 to 30 min. Cell extracts were treated as described under Materials and methods and 
assayed by western blotting. Phosphorylation of caveolin-1 (p-cav) was detected by using 
phosphospecific caveolin-1 monoclonal antibody that recognized only tyrosine 14-phosphorylated 
form of caveolin-1. Caveolin-1 was detected with polyclonal anti-caveolin-1 antibody, and α-tubulin 
was detected with monoclonal antibody to ensure equal loading. The amounts of phosphocaveolin-1 
were determined from densitometric analysis. Relative amounts of phosphocaveolin-1 were 
calculated by defining phosphocaveolin-1 in cells without any treatment as 1 and represented as the 
mean ± S.E. of three independent experiments. B) Dose response of PAR1-induced phosphorylation 
of caveolin-1 on tyrosine 14. After serum starvation for 24 h, both COS7 and HEK 293 cells were 
incubated with 10 to 500 μM SFLLRN at 37 °C for 15 min. Cell extracts were assayed by western 
blotting and the relative amounts of phosphocaveolin-1 were analyzed and represented as described 
in A. 
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Fig. 4. Involvement of p38 MAP kinase in 
PAR1-induced phosphorylation of caveolin-1. A) 
Effect of SB203580 on PAR1-induced 
phosphorylation of caveolin-1. HEK 293 cells stably 
expressing PAR1 were serum starved for 24 h and 
then preincubated in the absence or presence of 
SB203580 5 μM for 2 h. Cell extracts were assayed 
by western blotting as described in Fig. 3. Phospho 
p38 MAPK (pp38) was detected with a 
phosphospecific p38 polyclonal antibody that only 
recognized the active phosphorylated form of p38 
MAP kinase. B) Quantification of the amounts of 
phosphocaveolin-1 obtained in A. Relative amounts 
of phosphocaveolin-1 were calculated by defining 
phosphocaveolin-1 in cells without the treatment of 
both SFLLRN and SB203580 as 1. The quantitative 
results were represented as the mean ± S.E. of three 
independent experiments. C) Effect of dominant 
negative p38 MAP kinase on PAR1-induced 
phosphorylation of caveolin-1. HEK 293 cells 
transiently transfected with a IPTG-inducible p38 
dominant negative mutant were treated with 5 mM 
IPTG for 48 h to induce the expression of dominant 
negative p38 MAP kinase (p38AF). After IPTG 
treatment for 24 h, cells were serum starvation for 
24 h. Both sets of cells were stimulated in the 
absence and presence of 100 μM SFLLRN at 37 °C 
for 15 min. Cell extracts were assayed by western 
blotting as described in A. D) Quantification of the 
amounts of phosphocaveolin-1 obtained in C. 
Relative amounts of phosphocaveolin-1 were 
calculated by defining phosphocaveolin-1 in cells 
without the treatment of both of SFLLRN and IPTG 
as 1. The quantitative results were represented as the 
mean ± S.E. of  two independent experiments. 
 
 
 
 
 
 
 
 
 
3.5. Involvement of the Src family kinase in PAR1-induced phosphorylation of caveolin-1 
 
Tyrosine 14 of caveolin-1 was identified as the principal site of phosphorylation by 
c-Src [24]. Since PAR1 could stimulate Src kinase activity [10], it is possible that the Src 
family kinase is involved in PAR1-induced phosphorylation of caveolin-1 on tyrosine 14. 
Pretreatment of HEK 293 cells stably expressing PAR1 with PP1, a Src family kinase 
inhibitor, for 90 min completely blocked the phosphorylation of caveolin-1 after SFLLRN 
stimulation for 15 min (Fig. 5), indicating that activation of the Src family kinase was 
involved in PAR1-induced phosphorylation of caveolin-1. Thus, PAR1-induced 
phosphorylation of caveolin-1 on tyrosine 14 is mediated by the Src family kinase. To 
determine whether Src kinase is also involved in PAR1-induced activation of p38 MAP 
kinase, the phosphorylation of p38 MAP kinase was examined. In cells pretreated with PP1 
prior to SFLLRN stimulation, phosphorylation of p38 MAP kinase was partially inhibited 
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(Fig. 5, the lowest panel). Thus, PAR1-induced Src kinase activity could mediate the 
activation of p38 MAP kinase. These results suggest that PAR1-induced phosphorylation of 
caveolin-1 on tyrosine 14 is mediated by Src kinase and its downstream p38 MAP kinase. 
 
 
 
 
Fig. 5. Involvement of Src family kinase in PAR1-induced phosphorylation of caveolin-1. A) Effect of 
PP1 on PAR1-induced phosphorylation of caveolin-1. HEK 293 cells stably expressing PAR1 were 
serum starved for 24 h. Cells were preincubated in the absence or presence of 10 μM PP1 for 90 min, 
and both sets of cells were stimulated with 100 μM SFLLRN at 37 °C for 15 min. Cell extracts were 
assayed by western blotting as described in Fig.4.B) Quantification of the amounts of phosphocaveolin-1 
obtained in A. Relative amounts of phosphocaveolin-1 were calculated by defining phosphocaveolin-1 in 
cells without the treatment of both SFLLRN and PP1 as 1. The quantitative results were represented as 
the mean ± S.E. of four independent experiments. 
 
 
3.6. Involvement of PTX sensitive G protein in PAR1-induced phosphorylation of 
caveolin-1 
 
Pertussis toxin (PTX) has been reported to prevent Gi proteins from interacting with the 
receptors [47]. Since PTX has been reported to partially inhibit PAR1-induced Src kinase 
activity [10], it is possible that Gi protein acts upstream of Src kinase to mediate the 
phosphorylation of caveolin-1 in response to PAR1 activation. To determine whether Gi 
protein is involved in PAR1-induced phosphorylation of caveolin-1, HEK 293 cells stably 
expressing PAR1 were pretreated with PTX for 20 h to examine its effect on phosphorylation 
of caveolin-1. As shown in Fig. 6, stimulation of PAR1 by SFLLRN resulted in the increase 
of the phosphorylation of caveolin-1 on tyrosine 14. The same treatment also resulted in the 
increased levels of nonphospho-tyrosine 530 of Src (tyrosine 527 in avian Src), an active form 
of Src. However, pretreatment of the cells with PTX inhibited both effects induced by PAR1 
(Fig. 6). The result indicates that a Gi-linked Src kinase pathway is involved in PAR1-induced 
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phosphorylation of caveolin-1 on tyrosine 14. In this experiment, the phosphorylation of p38 
MAP kinase was also examined to determine whether Gi protein is involved in PAR1-induced 
activation of p38 MAP kinase. In cells pretreated with PTX prior to SFLLRN stimulation, 
phosphorylation of p38 MAP kinase was partially inhibited (Fig. 6, the lowest panel). These 
results indicate that PAR1-induced activation of p38 MAP kinase is mediated by a Gi-linked 
Src kinase pathway. Thus, p38 MAP kinase may act downstream of Gi-linked Src kinase to 
mediate PAR1-induced phosphorylation of caveolin-1 on tyrosine 14. 
 
 
 
 
Fig. 6. Involvement of PTX-sensitive G protein in PAR1-induced phosphorylation of caveolin-1. A) 
Effect of PTX on PAR1-induced phosphorylation of caveolin-1. HEK 293 cells stably expressing 
PAR1 were serum starved for 24 h. Cells were preincubated in the absence or presence of 100 ng/ml 
PTX for 20 h and then were stimulated with 100 μM SFLLRN at 37 °C for 15 min. Cell extracts were 
assayed by western blotting as described in Fig. 4. Nonphosphorylated Src (nonphospho-Src) at 
tyrosine 530 was detected by a nonphospho-Src polyclonal antibody which recognized the active form 
of Src. B) Quantification of the amounts of phosphocaveolin-1 obtained in A. Relative amounts of 
phosphocaveolin-1 were calculated by defining phosphocaveolin-1 in cells without the treatment of 
both SFLLRN and PTX as 1. The quantitative results were represented as the mean ± S.E. of three 
independent experiments. 
 
 
 
3.7. Negative regulation of Src kinase activity by the association of phosphocaveolin-1 
with Csk after PAR1 activation 
 
Tyrosine 14-phosphorylated caveolin-1 has been reported to recruit Csk and then 
inactivate Src kinase by phosphorylation of its tyrosine 527 under oxidative stress [29]. We 
first examined whether Csk is associated with phosphocaveolin-1 through its functional SH2 
domain in response to PAR1 activation. In these experiments, HEK 293 cells were transfected 
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with caveolin-1 or caveolin-1/Y14F mutant together with Csk or CskS109C mutant. 
Caveolin-1/Y14F mutant that could not be phosphorylated at tyrosine 14 was used to 
determine the binding function of phosphotyrosine; CskS109C mutant with a defect in the 
FLVRES motif of the SH2 domain was used to examine the requirement of SH2 domain to 
bind with phosphotyrosine-containing proteins. Both Csk and CskS109C mutant contained a 
hemagglutinin epitope tag allowing them to be separated from the endogenous Csk protein 
during immunoprecipitation. The association of phosphocaveolin-1 and Csk was examined by 
performing immunoprecipitation of HA-tagged Csk from the cells. In whole cell lysates, 
phosphocaveolin-1 was dramatically induced in HEK 293 cells overexpressing caveolin-1 
with either HA-tagged Csk or HA-tagged CskS109C in the absence and presence of SFLLRN 
stimulation (Fig. 7A, lanes 3, 4, 7, and 8). In cells overexpressing caveolin-1/Y14F and 
HA-tagged Csk, only endogenous phosphocaveolin-1 was detected, despite an overexpression 
of caveolin-1 (Fig. 7A, lanes 5 and 6). 
 
In HA-tagged Csk immunoprecipitates, additional phosphocaveolin-1 and caveolin-1 
could be detected only from cells overexpressing caveolin-1 and Csk after SFLLRN 
stimulation for 10 min (Fig. 7A, lane 12). However, neither phosphocaveolin-1 nor caveolin-1 
was detected from cells coexpressing HA-tagged Csk with caveolin-1/Y14F mutant or with its 
control pCEP4 vector (Fig. 7A, lanes 9, 10, 13, and 14). These results indicate that in 
response to PAR1 activation, phosphocaveolin-1 could bind to Csk, whereas caveolin-1 could 
not bind to Csk if its tyrosine 14 was mutated to phenylalanine. To further determine whether 
the SH2 domain of Csk is essential for the binding of phosphocaveolin-1, HA-tagged Csk 
immunoprecipitates from cells coexpressing CskS109C, a mutant with defective SH2 domain, 
and caveolin-1 in HEK 293 cells were examined. No phosphocaveolin-1 was detected in 
HA-tagged CskS109C immunoprecipitates (Fig. 7A, lanes 15 and 16), despite an 
overinduction of phosphocaveolin-1 in the cell lysates (Fig. 7A, lanes 7 and 8). These results 
indicate that the SH2 domain of Csk was necessary to bind tyrosine 14-phosphorylated 
caveolin-1 after PAR1 activation. 
 
Next, we determined whether the recruitment of Csk by phosphocaveolin-1 could 
phosphorylate tyrosine 530 of Src to downregulate PAR1-induced Src activation. The levels 
of phosphorylation of tyrosine 530 of Src in HEK 293 cells transfected with caveolin-1, 
caveolin-1/Y14F, or control pCEP4 vector were examined after SFLLRN stimulation. In cells 
transiently transfected with caveolin-1/Y14F or control pCEP4 vector, the levels of 
phosphorylation of tyrosine 530 of Src decreased after SFLLRN stimulation for 5 min (Fig. 
7B, lanes 2, 8, and 11). By contrast, in cells transiently transfected with caveolin-1, the levels 
of phosphorylation of tyrosine 530 of Src increased, which was associated with an 
overinduction of phosphocaveolin-1, with SFLLRN stimulation from 5 to 15 min (Fig. 7B, 
lanes 5 and 6). The increase of phosphorylation of tyrosine 530 of Src in cells overexpressing 
caveolin-1 suggests that PAR1-induced Src activation might be inhibited in these cells. We 
then examined the activity of Src kinase by detecting the levels of nonphospho-tyrosine 530 
of Src, an active form of Src. In this experiment, caveolin-1/Y14F mutant was used to 
differentiate whether the inhibitory effect of PAR1-induced Src activation is resulted from the 
association of phosphocaveolin-1 with Csk or from direct inhibition of caveolin-1 on Src 
kinase activity. In cells transiently transfected with caveolin-1/Y14F or control pCEP4 vector, 
the level of activated Src increased with SFLLRN stimulation from 5 to 15 min (Fig. 7B, 
lanes 2, 3, 8, 9, 11 and 12, and C), even though caveolin-1 was overexpressed in cells 
transfected with caveolin/Y14F as compared with the control cells, but the induction of 
phosphocaveolin-1 was similar in both cells (Fig. 7B, lanes 7–12). By contrast, in cells 
transiently transfected with caveolin-1, the level of activated Src decreased, which was 
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associated with an overinduction of phosphocaveolin-1, with SFLLRN stimulation from 5 to 
15 min (Fig. 7B, lanes 5 and 6, and C). Thus, overinduction of phosphocaveolin-1 after 
SFLLRN stimulation downregulates PAR1-induced Src kinase activity. The results indicate 
that Src kinase activity is negatively regulated through the recruitment of Csk by 
phosphocaveolin-1 in response to PAR1 activation. 
 
 
 
Fig. 7. Negative regulation of Src kinase activity by the association of phosphocaveolin-1 with Csk after 
PAR1 activation. A) Association of phosphocaveolin-1 and Csk. HEK 293 cells stably expressing PAR1 
were transfected with the plasmids of HA-tagged Csk (HA-Csk) or HA-tagged CskS109C (HA-CskS109C) 
together with the plasmids of caveolin-1 (Cav), caveolin-1/Y14F (Cav/Y14F), or pCEP4 vector. After 48 h 
transfection, cells were serum starved for 24 h and incubated in the absence or presence of 100 μM SFLLRN 
at 37 °C for 10 min. Cells were subjected to immunoprecipitation with HA-conjugated agarose beads for the 
isolation of HA-tagged Csk or HA-tagged CskS109C. Whole cell lysates and immunoprecipitates (IP) were 
subjected to SDS-PAGE and assayed by western blotting. Csk was detected by monoclonal anti-Csk antibody. 
Phosphocaveolin-1, caveolin-1 and tubulin were detected as described in Fig. 3. B) Attenuation of Src kinase 
activity through the phosphorylation of tyrosine 530 of Src. HEK 293 cells stably expressing PAR1 were 
transiently transfected with caveolin-1 (Cav), caveolin-1/Y14F (Cav/Y14F), or pCEP4 vector. After 48 h 
transfection, HEK 293 cells were serum starved for 24 h and then incubated in the absence or presence of 
100 μM SFLLRN at 37 °C for 5 or 15 min. Cell lysates were subjected to SDS-PAGE and assayed by 
western blotting. Nonphosphorylated Src (nonphospho-Src) or phosphorylated Src (phospho-Src) at tyrosine 
530 were detected by nonphospho-Src or phospho-Src polyclonal antibodies that recognized the active or 
inactive form of Src, respectively. Phosphocaveolin-1, caveolin-1 and tubulin were detected as described in 
Fig.3.C) Quantification of the amounts of nonphospho-Src obtained in B. The amounts of nonphospho-Src 
were determined from densitometric analysis of unstimulated and stimulated cells transiently transfected with 
caveolin-1, caveolin-1/Y14F, or pCEP4 vector, and shown as fold increase over control. The quantitative 
results were represented as the mean ± S.E. of three independent experiments. Statistical significance 
compared with CEP4 was determined using a paired t test (*p < 0.05). 
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4. Discussion 
 
PAR1-induced Src activation plays a key role in cell-proliferative responses. However, 
the mechanisms by which PAR1 regulates the activity of Src kinase are not completely 
understood. In this study, we show a novel mechanism for the feedback regulation of Src 
kinase in PAR1 signaling. After PAR1 activation, Csk negatively regulates Src kinase activity 
by the association with phosphocaveolin-1. This association occurs through the SH2 domain 
of Csk by binding with the tyrosine 14-phosphorylated caveolin-1. The finding that 
PAR1-induced phosphorylation of caveolin-1 requires a Gi-linked Src kinase pathway 
suggests that G proteins also mediate the phosphorylation of caveolin-1 induced by GPCRs. 
Since PAR1 is partially localized in caveolae and associated with caveolin-1, the feedback 
regulation of PAR1-induced Src kinase activity by phosphocaveolin-1 might occur in 
caveolae. Our findings provide the first evidence for the involvement of caveolin-1 in PAR1 
signaling. 
 
Two important phosphorylation sites, tyrosine 416 and tyrosine 527, regulate Src 
kinase [48]. Src undergoes autophosphorylation at tyrosine 416, and its phosphorylation 
increases kinase activity. Under basal conditions, most Src is phosphorylated at tyrosine 527, 
and phosphotyrosine 527 binds intramolecularly with the SH2 domain of Src to keep it in an 
inactive conformation. The Tyr527Phe Src mutant has been reported to be more active than 
other forms and can induce anchorage-independent growth in cell culture and in tumors in 
vivo [49], indicating a key role of tyrosine 527 in the regulation of Src kinase activity. 
Therefore, downregulation of Src kinase activity by the phosphorylation of tyrosine 527 after 
PAR1 activation could be important in PAR1 signaling. The scaffolding domain, residues 82–
101, of caveolin-1 can directly interact with Src and inhibit its autophosphorylation at tyrosine 
416 [50]. This observation raised the possibility that overexpression of caveolin-1 could result 
in the inhibition of PAR1-induced Src activation. However, our results showed that after 
PAR1 activation, a transient increase in phosphorylation of caveolin-1 on tyrosine 14 was 
associated with a rapid decrease in kinase activity of Src only in cells overexpressing 
caveolin-1 but not in cells overexpressing caveolin-1/Y14F (Fig. 7B and C). Therefore, 
PAR1-induced phosphorylation of caveolin-1 on tyrosine 14 serves a regulatory role in the 
Src-kinase feedback loop of transient activation and attenuation. 
 
Csk is not a membrane-associated polypeptide and lacks a membrane-targeting motif. 
To date, two tyrosine-phosphorylated proteins, caveolin-1 and Csk-binding protein (Cbp), 
have been reported to recruit Csk from the cytosol to a specific site at the cell membrane to 
target the Src family kinase [29,32,51]. Of interest, both caveolin-1 and Cbp are located at a 
specific microdomain called lipid rafts. In our study, activation of PAR1 resulted in a 
transient increase of phosphorylation of caveolin-1 on tyrosine 14. Phosphocaveolin-1 further 
recruited Csk to return Src activity back to the basal state. The findings are similar to the 
previous observations for cells under oxidative stress [29,32]. Thus, transient phosphorylation 
of caveolin-1 after PAR1 activation might occur in caveolae, a subset of lipid rafts, to fine 
tune Src kinase activity for the appropriate regulation of cellular responses. 
 
Activation of the p38 MAP kinase pathway, but not the p42/44 MAP kinase pathway, 
has been reported to be required to induce tyrosine phosphorylation of caveolin-1 in response 
to hyperosmotic stress [30]. Consistent with their observations, using a specific p38 MAP 
kinase inhibitor, SB203580, and the dominant negative form of p38 MAP kinase, we found 
that most of the phosphorylation of caveolin-1 occurred through the activation of the p38 
MAP kinase pathway. When we used the specific inhibitors, PD98059 and U0126, of the 
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p42/44 MAP kinase pathway, we did not observe any reduction in tyrosine phosphorylation of 
caveolin-1 (T.-L. Lu and H.-W. Fu, unpublished observation). Therefore, the signaling 
pathways of tyrosine phosphorylation of caveolin-1 induced by PAR1 and by hyperosmotic 
stress might be quite similar. However, the detailed mechanisms remain to be clarified. 
 
Caveolae are important in the regulation of endocytosis and signaling of GPCRs. A 
number of GPCRs shuttle inside and outside of caveolae upon agonist binding. Some of them 
are localized in the caveolae independent of agonist binding. For example, endothelin receptor 
subtype A is mainly in caveolae and enters cells via caveolae [17]. β2-adrenergic receptor is 
also localized in caveolae but leaves after agonist binding and then is internalized via 
clathrin-coated pits [52,53]. In our study, PAR1 was partially localized in caveolae and 
associated with caveolin-1 in the absence of an agonist, indicating that localization of PAR1 
in caveolae was ligand-independent. In addition, caveolae were not involved in the 
internalization of PAR1. Thus, the localization of PAR1 in caveolae should be important in 
the regulation of PAR1 signaling. Our study showed that Gi protein and Src kinase were all 
upstream signaling molecules that mediated PAR1-induced phosphorylation of caveolin-1. 
Both of them were reported to be associated with caveolin-1 and localized in caveolae [23,54]. 
Therefore, caveolae might serve as compartments for recruiting components involved in 
PAR1-mediated signaling pathways to support the efficient and rapid coupling of receptors to 
the system with more than one effector. 
 
Since proteolytic activation of PAR1 is irreversible, the mechanisms that contribute to 
the termination of receptor signaling are critical in determining the magnitude and duration of 
thrombin-stimulated signaling in cells. Lysosomal degradation and desensitization of the 
receptor are the two well-established mechanisms for terminating the signaling of PAR1 at the 
level of receptors. In our study, new evidence is presented to support that phosphocaveolin-1 
could facilitate the termination of PAR1 signaling at the level of its downstream molecules. In 
response to PAR1 activation, phosphocaveolin-1 recruits Csk to downregulate Src kinase 
activity. The pathways established are summarized in the scheme shown in Fig. 8. After 
PAR1 activation, caveolin-1 is phosphorylated on tyrosine 14 through a Gi-linked Src kinase 
pathway and p38 MAP kinase. The association of phosphocaveolin-1 with Csk further 
attenuates PAR1-induced Src kinase activity. The regulation of PAR1-induced Src kinase 
activity described here might serve as a paradigm for other GPCR-mediated signaling 
pathway. 
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Fig. 8. Proposed signal transduction mechanism underlying PAR1-induced phosphorylation of 
caveolin-1 and feedback inhibition of Src kinase by the association of phosphocaveolin-1 and Csk. 
Activation of PAR1 by SFLLRN leads to phosphorylation of caveolin-1 on tyrosine 14 (pY14). The 
phosphorylation is mediated by PTX-sensitive Gi protein-linked Src kinase. p38 MAP kinase, which 
acts downstream of Src, is also involved. Phosphorylated caveolin-1 in turn leads to the recruitment of 
Csk through its SH2 domain to phosphorylate tyrosine 530 (pY530) of Src and attenuate 
PAR1-induced Src activation. These signaling events might occur in caveolae. 
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